Mizuho Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $31
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $26 to $31.
Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $26 to $31.